1. Home
  2. ELMD vs IFRX Comparison

ELMD vs IFRX Comparison

Compare ELMD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electromed Inc.

ELMD

Electromed Inc.

SELL

Current Price

$23.00

Market Cap

204.1M

Sector

Health Care

ML Signal

SELL

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.05

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELMD
IFRX
Founded
1992
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.1M
225.5M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
ELMD
IFRX
Price
$23.00
$1.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
★ $48.50
$8.29
AVG Volume (30 Days)
38.8K
★ 1.1M
Earning Date
11-10-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 52.94
N/A
EPS
★ 0.32
N/A
Revenue
★ $54,716,000.00
N/A
Revenue This Year
$11.55
N/A
Revenue Next Year
$10.94
N/A
P/E Ratio
$72.69
★ N/A
Revenue Growth
★ 13.83
N/A
52 Week Low
$22.67
$0.80
52 Week High
$47.40
$2.95

Technical Indicators

Market Signals
Indicator
ELMD
IFRX
Relative Strength Index (RSI) 27.51 27.04
Support Level $23.03 $0.81
Resistance Level $24.99 $1.07
Average True Range (ATR) 1.24 0.15
MACD -0.29 -0.02
Stochastic Oscillator 8.17 0.00

Price Performance

Historical Comparison
ELMD
IFRX

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures and markets airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The company markets its products in the U.S. to the homecare and hospital markets. Its product includes the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The company operates in a single segment: developing, manufacturing, and marketing medical equipment. The company generates revenue from Homecare, Hospital, Homecare Distributor, and Other.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: